Sunrest Lifescience Limited H1 Revenue Falls 6.2% to ₹31.9 Crore
Key highlights
- Sunrest Lifescience reported H1 FY27 revenue of ₹31.9 crore, down 6.2% year on year.
- H1 FY27 net profit was ₹0.6 crore, down 13.7% from H1 FY26.
- Operating profit was ₹2.8 crore and the operating margin was 8.9% in H1 FY27.
- The board approved standalone and consolidated unaudited results on 14 November 2026, 45 days after the half-year end.
powered by IRIS

Sunrest Lifescience Limited reported H1 FY27 revenue of ₹31.9 crore, down 6.2% year on year, while net profit fell 13.7% to ₹0.6 crore for the half year ended 30 September 2026. The company’s board approved the standalone and consolidated unaudited results on 14 November 2026.
Know Sunrest Lifescience inside out
Results, valuation, peers and who's buying, in one view.
What did Sunrest Lifescience report for H1 FY27?
Sunrest Lifescience reported revenue of ₹31.9 crore for April-September 2026, compared with the corresponding half-year period a year earlier. Revenue was also 13.4% lower than the immediately preceding half year, according to the reported H1 FY27 results summary.
Operating profit was ₹2.8 crore, an increase of 15.2% year on year, although it was 58.2% lower than the previous half year. The operating profit margin stood at 8.9%. Net profit was ₹0.6 crore, down 13.7% from H1 FY26 and 91.3% from the preceding six-month period.
The reported earnings per share for H1 FY27 was ₹2.65. This was stated to be 562.5% above the H1 FY26 figure and 32.7% below the prior-half figure. The provided results summary does not set out the individual items behind the change in earnings per share.
When did Sunrest Lifescience approve the results?
Sunrest Lifescience approved its standalone and consolidated unaudited financial results for the half year ended 30 September 2026 at a board meeting held on Saturday, 14 November 2026. The company had informed the National Stock Exchange on 2 November that its board would consider the half-yearly results and other business matters on that date.
The meeting began at 3:30 pm and concluded at 6:45 pm, according to the board-meeting outcome details provided. The outcome confirmed approval of the standalone and consolidated unaudited results. The cover announcement itself did not contain the detailed profit and loss statement figures.
The result approval followed a familiar filing timetable for the company. Its previous April-September results were filed on 13 November 2025 and 14 November 2024. The supplied historical record shows that Sunrest Lifescience has filed its half-yearly results between 44 and 60 days after the end of the relevant reporting period over the past four half years.
How does H1 FY27 compare with Sunrest Lifescience’s earlier performance?
H1 FY27 revenue and profit were below the levels reported for the corresponding prior period and the March 2026 half year. The ₹31.9 crore revenue figure compares with ₹34.01 crore of consolidated sales reported for September 2025, while the March 2026 half-year revenue was ₹36.82 crore.
The earlier consolidated results showed operating profit of ₹2.45 crore for September 2025 and ₹6.75 crore for March 2026. Net profit was ₹0.66 crore in September 2025 and ₹6.57 crore in March 2026. Against that base, the current half-year operating profit was higher than the September 2025 level, but net profit was lower.
For the financial year ended 31 March 2026, Sunrest Lifescience reported consolidated revenue of ₹70.63 crore, operating profit of ₹10.21 crore and net profit of ₹8.00 crore. Its consolidated operating margin for that year was 14.46%, compared with the 8.9% reported for H1 FY27.
The company’s annual report also stated that standalone turnover for FY26 was ₹33.26 crore, compared with ₹33.12 crore in FY25. Standalone profit after tax increased to ₹3.09 crore from ₹2.00 crore. These standalone annual figures should not be directly compared with the H1 FY27 summary without considering the difference between standalone and consolidated reporting bases.
Got a follow-up? Ask IRIS
What should investors assess after the H1 FY27 result?
Investors will assess the decline in revenue and net profit alongside the change in operating profitability. Although operating profit rose year on year, the operating margin of 8.9% was below the 18.33% margin reported for the March 2026 half year. The available data does not provide a detailed explanation for the lower margin or the sharp sequential fall in net profit.
The board agenda covered financial results and other business matters. The supplied board outcome confirms the results approval but does not state that a dividend, bonus issue, stock split or fund-raising proposal was approved. Investors should therefore rely on subsequent exchange filings for any corporate action or additional financial detail.
No share-price movement, valuation data, management commentary or forward-looking guidance was included in the supplied material. As a result, the immediate market impact cannot be quantified from the available disclosures. The key reported facts are the 6.2% annual decline in revenue, the 13.7% decline in net profit, and the lower operating margin compared with the preceding half year.
Why is the timing of the filing relevant?
The 14 November approval date placed Sunrest Lifescience’s H1 FY27 disclosure 45 days after the 30 September period end. That is consistent with the company’s past reporting pattern. H1 FY26 results were filed 44 days after the period end, while H1 FY25 results were filed after 45 days.
Timely half-yearly filings give shareholders a formal update on financial performance and provide the audited or limited-review framework required under applicable listing regulations. The company’s earlier disclosures state that its H1 FY26 revised financial results were reviewed by the audit committee and approved by the board, with an unmodified report from the statutory auditor.
Conclusion
Sunrest Lifescience’s H1 FY27 numbers show a 6.2% year-on-year reduction in revenue to ₹31.9 crore and a 13.7% decline in net profit to ₹0.6 crore. Operating profit increased from the prior-year half, but the 8.9% operating margin and the sequential reduction in revenue, operating profit and net profit are the central financial changes in the disclosure.
The next item to watch is any detailed standalone and consolidated financial statement or follow-up exchange filing that explains the movement in expenses, margins and earnings. Investors may also monitor whether Sunrest Lifescience announces any corporate action, as none was confirmed in the supplied board-meeting outcome.


